Rapid Equilibrium Dialysis

A Transforming Technology for Plasma Protein Binding Assays

Determining the extent to which a molecule binds to plasma proteins is a critical phase of drug development because it influences compound dosing, efficacy, clearance rate and potential for drug interactions. This determination is enabled by equilibrium dialysis, an accepted standard method for reliable estimation of the nonbound drug fraction in plasma. Although it is the preferred method, equilibrium dialysis is labor-intensive, time-consuming, cost-prohibitive and difficult to automate. The RED Device for rapid equilibrium dialysis was developed in close association with the pharmaceutical industry to specifically address these issues, accelerating lead optimization and reducing attrition rate. In addition to plasma protein binding, the device is used for determining drug partition between red blood cell and plasma; protein binding of liver microsomes to improve the correlation between in vitro and in vivo intrinsic clearance; and the competition between tissue protein binding against plasma proteins. The RED device offers the molecular weight cutoff (MWCO) of 8,000 Da.

Ordering Information